SecBot SecBot
25-NSE ·Filed May 11, 2026

KZR

Kezar Life Sciences, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001354457-26-000433
Notable filing: 25-NSE
Actionable Insight • Neutral

No further trading on Nasdaq; shareholders who have not tendered shares should do so promptly. Monitor for any CVR valuation developments.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK AT ENTRY AT T+1
Entry
$7.29
T+0 close · May 11, 2026 · via day close
Latest settled
0.00%
T+1 · $7.29
Vs SPY
+0.14%
α at T+1
Next horizon
T+5
due 6mo ago
  1. T+0 · May 11 $7.29entry
  2. T+1 · 6mo ago 0.00%α +0.14% · $7.29
  3. T+5 · due 6mo ago Pending
  4. T+20 · due 5mo ago Pending
  5. T+60 · due 3mo ago Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nasdaq filed a 25-NSE notification to remove Kezar Life Sciences' common stock from listing, effective immediately. This follows the completion of Aurinia Pharma's acquisition of Kezar on the same day, in which shareholders received $6.955 per share plus contingent value rights.

Key Facts

  • Delisting effective May 11, 2026 per Rule 12d2-2(a)(3).
  • Acquisition by Aurinia Pharma U.S., Inc. completed prior to delisting; shareholders received $6.955 per share plus one CVR per share.
  • Kezar is now a wholly owned subsidiary of Aurinia.

Financial Impact

Shareholders received $6.955 per share in cash plus contingent value rights; no further trading expected.

stock price

Risk Factors

  • CVR may pay out less than anticipated or nothing.
  • Potential for shareholder litigation if acquisition process challenged.
  • Loss of liquidity as stock is delisted.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
25-NSE Filing (Primary)0001354457-26-000433
Document: 0001354457-26-000433-index-headers.html0001354457-26-000433
Document: 0001354457-26-000433-index.html0001354457-26-000433
Document: 0001354457-26-000433.txt0001354457-26-000433

Track record

3 reports on KZR

Performance horizon
Filters
  1. May 15, 202626w ago EFFECT Bearish 5/10 Entry $7.29 No price data
  2. May 11, 202627w ago 25-NSE Neutral 2/10 Viewing Entry $7.29 No price data
  3. May 11, 202627w ago 8-K Neutral 8/10 Entry $7.29 No price data
Showing 3 of 3

US Market Status

Market Closed · Opens in 6h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026